Cephalon
Teva denies wrongdoing in Cephalon pay-to-delay deal hearing
March 14, 2018Research and Development, Sales and Marketing Cephalon, Pay to delay, Provogil, Teva, pay-to-delay, pharma
Teva has denied allegations from the European Commission (EC) that it engaged in illegal anti-competitive pay-to-delay tactics to maintain its …
Mylan pays $96.5 million to settle pay-for-delay case
February 7, 2017Research and Development, Sales and Marketing Cephalon, Mylan, Teva, antitrust
Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …
Teva settles generic ‘pay-to-delay’ case for $1.2 billion
May 29, 2015Sales and Marketing Cephalon, FTC, Teva, modafinil, provigil
Teva Pharmaceuticals has agreed to a $1.2 billion settlement for paying generic drug makers to delay challenging the patent for …
Teva faces $512m fine in generic Provigil row
April 22, 2015Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil
Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …
Pfizer recalls oral contraceptive for packaging errors
February 2, 2012Manufacturing and Production Akrimax, Bedford, Cephalon, Lo/Ovral-28, Pfizer, Teva
Pfizer has been forced to recall a large volume of oral contraceptive packs distributed in the US market because a …
Teva’s Cephalon acquisition could be delayed
June 15, 2011Manufacturing and Production, Research and Development, Sales and Marketing Cephalon, Teva
The Federal Trade Commission has requested more information about Teva’s deal with Cephalon, potentially delaying the purchase by a month. …
Cephalon accepts Teva’s $6.8 billion white knight bid
May 3, 2011Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics
Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …
Valeant makes $5.7 billion hostile bid for Cephalon
March 31, 2011Research and Development, Sales and Marketing Cephalon, Valeant
Valeant has made a hostile bid for Cephalon, but analysts believe its offer is too low for the deal to …
Cephalon buys Gemin X for $225 million
March 24, 2011Research and Development Cephalon, lung cancer
Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …
Allergan marketing breaches discredited industry
March 22, 2011Medical Communications Allergan, Cephalon, PMCPA
Allergan, the manufacturer of Botox, has been censured for several breaches of the ABPI Code of Practice. The PMCPA watchdog …
Cephalon in trouble over party spirit
February 11, 2011Medical Communications ABPI, ABPI Code of Practice, Cephalon, PMCPA, industry reputation
Cephalon has been criticised by UK authorities for bankrolling “excessive” hospitality at a conference in Lisbon.The company was cited by …
Cephalon’s Paul Harmon joins IPHA board
January 10, 2011Sales and Marketing Cephalon, IPHA, Paul Harmon, appointment, sales and marketing
Cephalon’s Paul Harmon has been elected to the prescription medicines division strategy board of Irish pharma association IPHA, a role …
Cephalon chairman takes leave of absence
September 2, 2010Research and Development, Sales and Marketing Cephalon, appointment, research and development, sales and marketing
Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …
Cephalon completes acquisition of generics firm Mepha
April 16, 2010Sales and Marketing Cephalon, generics
Specialist pharmaceutical company Cephalon has completed the $615.4 million acquisition of Mepha. Based in Switzerland, Mepha specialises in using reformulation …
Cephalon to develop new class of cancer drug
March 19, 2010Research and Development CRT, Cancer, Cancer Research UK, Cephalon
Pennsylvania-based Cephalon has signed a deal with the discovery arm of charity Cancer Research UK to develop a new class …
